1756-1757 / 2239
Taking patient specific QA further…
“none of the approaches tested to verify IMRT plans by means of gamma
analysis using 3%/3 mm or 2%/2 mm criteria solve the problem of
evaluating treatment plans. Neither is it clear whether global 3D gamma
analysis is superior to local 3D gamma analysis.” - Carrasco et al 2012
“a suitable alternative for evaluating and reporting the measured planar
differences is to transfer their impact to the plan DVH and then to compare
the resulting DVHs with the clinical tolerances of the PTV and OAR.” -
48
Carrasco et al 2012
“the essence of patient-specific IMRT QA is to ensure that the dose
distribution that is going to be delivered to the patient is of the same
comparable quality as the approved plan, and such quality is evaluated by
patient dose statistics and DVH curves.” - Zhen – et al 2011
“The evolution from gamma passing rates to DVH based metrics is natural
in this way.” – Zhen –et al 2011
Utrecht 2016